Home » Healthcare » Pharmaceuticals » Respiratory Tract Infection Treatment Market

Respiratory Tract Infection Treatment Market By Disease (Upper Respiratory Tract Infection, Lower Respiratory Tract Infection), By Drug Class (Antibiotics, Antiviral, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppresant, Nasal Decongestant) – Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Summary
Table Of Content

Market Insights

This report on the global respiratory tract infection treatment market studies various diseases and drug classes. According to the World Health Organization, three million people died from COPD in 2015. The respiratory tract infection treatment market is being driven by a constantly changing climate, rising air pollution, and an increasing desire to maintain personal hygiene. The limiting factors related to this market are the rising incidence of antibiotic resistance and adverse events relating to the consumption of NSAIDs, which will hinder the growth of the respiratory infection treatment market.

Technological advancements in pharmacokinetics and drug screening for adverse events will result in deep market penetration. The increasing consumption of cheap generic medicines will hinder the branded drug market. The drugs in the pipeline are Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, PT010 (AstraZeneca), etc.

For the purpose of this study, the various diseases studied include upper respiratory tract infection, lower respiratory tract infection, and others. Drug classes studied for the purpose of this research include antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nose decongestants, and others.

Upper respiratory tract infection is further segmented as “common cold,” “sinusitis,” “epiglottitis,” and “laryngitis,” while lower respiratory tract infection is further segmented as “flu, bronchitis, pneumonia, asthma, COPD, and respiratory syncytial virus.” The geographic segmentation of the global respiratory tract infection treatment market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year. This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global respiratory tract infection treatment market.

Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global respiratory tract infection treatment market. The key players profiled in this report are Abbott Laboratories, Abbvie Inc., AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, and others.

Based on disease, the global respiratory tract infection treatment market is categorized into

Upper respiratory tract infection

Common cold
Sinusitis
Epiglottitis
Laryngitis

Lower respiratory tract infection

Flu
Bronchitis
Pneumonia
Chronic obstructive pulmonary disorder (COPD)
Asthma
Respiratory syncytial virus

A respiratory tract infection is one of the most common reasons for patients to visit the clinic or hospital. In the base year 2016, upper tract respiratory infection held the largest market in the diseased segment due to factors like the constant change in climate and rising air pollution, the rising number of patients suffering from the common cold as many types of viruses cause it, and gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered faces), and touching inanimate objects with contaminated hands.

Lower respiratory tract infection will be the fastest growing market in the diseased segment throughout the forecast period of 2017–2025, chiefly due to factors such as the rising number of airborne particulate matters that are exhumed by industrial chimneys and automobiles that cause lower respiratory tract irritation and infection.

On the basis of transmission, it might be hospital-acquired, ventilator-acquired, or community-acquired. Technological advancement in the exact diagnosis of the causative agent in order to determine the treatment regimen for diseases like asthma, COPD, and the respiratory syncytial virus will be a positive factor for the fast growth of the respiratory tract infection treatment market during the forecast period.

Based on drug class, the respiratory tract infection treatment market is categorized into

Antibiotics
Antibacterial
Cephalosporin (Ceftriaxone, Cefotaxime)
Penicillin (Amoxicillin, Ampicillin, and Methicillin)
B-lactamase inhibitors (sulbactam, clavulanic acid)
Antivirals
Ribavarin
Palivizumab
Ganciclovir
Vidarabine

Non-steroidal anti-inflammatory drugs (NSAIDs)

Paracetamol
Ibuprofen
Naproxen
Aspirin

Cough suppressants

Dextromethorphan
Pholcodine
Benzonatate
Diphenhydramine

Nasal decongestants

Phenylephrine
Oxymetazoline
Pseudoephedrine
Others

Respiratory tract infection treatment is seeing huge application due to factors such as the rising prevalence of respiratory tract infections, the constant change in climate, rising air pollution, and increasing cases of antibiotic resistance. In the base year, 2016, non-steroidal anti-inflammatory drugs (NSAIDS) held the largest market in the drug treatment segment, chiefly due to factors such as low cost, easy availability as OTC products, immediate symptomatic relief, and technological advancement in the drug formulation, e.g., micronized NSAIDs have desirable pharmacodynamic activity and an early excretion rate to overcome NSAID adverse events.

Antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period of 2017-2025, mainly due to factors such as their diverse application in various respiratory tract infections, improved pharmacokinetics to specifically target the respiratory tract infection (e.g., nebulized Aztreonam formulation is more effective than Aztreonam tablets), and technological advancements in the antibiotics industry are resulting in next-generation broad-spectrum antibiotics (e.g., methicillin formulated with branched polyethyleneimine polymer to counteract antibiotic-resistant cells).

Overall, the global respiratory tract infection treatment market is highly competitive, with multiple players like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim GmbH, Pfizer, Inc., and GlaxoSmithKline plc specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the market growth for respiratory tract infection treatment.

For the purpose of this study, the global respiratory tract infection treatment market is categorized into three segments:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

In 2016, North America was identified as the largest market for respiratory tract infection treatment. According to the Centers for Disease Control and Prevention (CDC), American adults have 2 to 3 colds per year with underlying symptoms such as a runny nose, sore throat, coughing, sneezing, headaches, and body aches. The growth is attributed mainly to the large population suffering from respiratory complications and the inclination to maintain personal hygiene, along with a favorable reimbursement scenario.

Europe is expected to be the second-largest market due to cool and damp weather favoring respiratory disease and regulatory approval for respiratory tract infection treatment products. The growth of the Asia Pacific respiratory tract infection treatment market is attributed to factors like the rising prevalence of respiratory illness among a huge population base, a competitive market due to manufacturers involved in respiratory tract infection treatment products, and the impact of monsoon weather in the South Asian countries.

However, factors such as developing health infrastructure, increasing disease awareness, and increasing demand for respiratory tract infection treatment products are going to fuel the growth of the respiratory tract infection treatment market in Latin America, the Middle East, and Africa in the near future.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Respiratory Tract Infection Treatment Market Portraiture
2.2 Global Respiratory Tract Infection Treatment Market, by Disease, 2016 (US$ Mn)
2.3 Global Respiratory Tract Infection Treatment Market, by Drug Class, 2016 (US$ Mn)
2.4 Global Respiratory Tract Infection Treatment Market, by Geography, 2016 (Value %)

Chapter 3 Global Respiratory Tract Infection Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Constantly changing climate and rise in air particulate matter due to automobile and industrial emission
3.3 Market Restraints
3.3.1 Rising prevalence of antibiotic drug resistance
3.4 Market Opportunities
3.4.1 Rapid industrialization in the developing countries lading to increased air and water pollution will drive the respiratory tract infection treatment market in Asia Pacific
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Respiratory Tract Infection Treatment, by Key Players

Chapter 4 Global Respiratory Tract Infection Treatment Market, By Disease
4.1 Introduction
4.2 Upper respiratory tract infection
4.2.1 Common cold
4.2.2 Sinusitis
4.2.3 Epiglottitis
4.2.4 Laryngitis
4.3 Lower respiratory tract infection
4.3.1 Flu
4.3.2 Bronchitis
4.3.3 Pnuemonia
4.3.4 Chronic obstructive pulmonary disease (COPD)
4.3.5 Asthma
4.3.6 Respiratory syncytial virus

Chapter 5 Global Respiratory Tract Infection Treatment Market, By Drug Class
5.1 Market Analysis
5.2 Antibiotics
5.2.1 Antibacterial
5.2.1.1 Cephalosporin (ceftriaxone, cefotaxime)
5.2.1.2 Penicillin antibiotic (amoxicillin, ampicillin)
5.2.1.3 B lactactamase inhibitors (sulbactum,clavulanic acid)
5.2.2 Antiviral
5.2.2.1 Ribavarin
5.2.2.2 Palivizumab
5.2.2.3 Ganciclovir
5.2.2.4 Vidarabine
5.3 Non-steroidal anti-inflammatory drug (NSAIDS)
5.3.1 Paracetamol
5.3.2 Ibuprofen
5.3.3 Naproxen
5.3.4 Aspirin
5.4 Cough suppresant
5.4.1 Dextromethorphan
5.4.2 Pholcodine
5.4.3 Benzonatate
5.4.4 Diphenhydramine
5.5 Nasal decongestant
5.5.1 Phenylephrine
5.5.2 Oxymetazoline
5.5.3 Pseudoephedrine
5.6 Others

Chapter 6 Global Respiratory Tract Infection Treatment Market, By Geography
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia Pacific
6.5 Latin America
6.5.1 Brazil
6.5.2 Mexico
6.5.3 Rest of Latin America
6.6 Middle East and Africa
6.6.1 GCC
6.6.2 Rest of Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.2 AstraZeneca
7.3 Abbvie Inc.
7.4 Boehringer Ingelheim GmbH
7.5 Cipla Pharmaceutical Company
7.6 GlaxoSmithkline plc
7.7 Pfizer Inc.
7.8 Merck & Co.
7.9 Novartis AG
7.10 F.Hoffman La Roche Ltd
7.11 Sanofi
7.12 Teva Pharmaceutical Industries Ltd.
7.13 Theravence Biopharma
7.14 Vertex Pharmaceuticals Inc.
7.15 Others

List of Figures

FIG. 1 Global Respiratory Tract Infection Treatment Market: Research Methodology
FIG. 2 Global Respiratory Tract Infection Treatment Market, by Disease, 2016 (US$ Mn)
FIG. 3 Global Respiratory Tract Infection Treatment Market, by Drug Class, 2016 (US$ Mn)
FIG. 4 Global Respiratory Tract Infection Treatment Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2016
FIG. 6 Market Positioning of Key Respiratory Tract Infection Treatment Vendors, 2016
FIG. 7 Common Cold Infection Market, 2015 – 2025 (US$ Mn)
FIG. 8 Sinusitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 9 Epiglottitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 10 Laryngitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 11 Flu Infection Market, 2015 – 2025 (US$ Mn)
FIG. 12 Bronchitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 13 Pneumonia Infection Market, 2015 – 2025 (US$ Mn)
FIG. 14 Chronic Obstructive Pulmonary Disease Infection Market, 2015 – 2025 (US$ Mn)
FIG. 15 Asthma Infection Market, 2015 – 2025 (US$ Mn)
FIG. 16 Respiratory Syncytial Virus Infection Market, 2015 – 2025 (US$ Mn)
FIG. 17 Antibiotics Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 18 Non-steroidal Anti-inflammatory Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 19 Cough Suppresant Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 20 Nasal Decongestant Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 21 Others Drug Class Market , 2015 – 2025 (US$ Mn)
FIG. 22 U.S. Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 23 Canada Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 24 U.K. Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 25 Germnay Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Europe Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 27 China Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 28 Japan Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Asia Pacific Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 30 Brazil Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 31 Mexico Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 32 Rest of Latin America Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 33 GCC Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 34 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Respiratory Tract Infection Treatment Market, By Disease, 2015-2025 (US$ Mn)
TABLE 2 Global Upper Respiratory Tract Infection Treatment Market, 2015-2025 (US$ Mn)
TABLE 3 Global Lower Respiratory Tract Infection Treatment Market, 2015-2025 (US$ Mn)
TABLE 4 Global Respiratory Tract Infection Treatment Market, By Drug Class, 2015-2025 (US$ Mn)
TABLE 5 Global Respiratory Tract Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 North America Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Middle East and Africa Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Abbott Laboratories : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 AstraZeneca : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Abbvie Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 14 Boehringer Ingelheim GmbH : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 15 Cipla Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 16 GlaxoSmithKline plc : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 17 Pfizer Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 18 Merck & Co. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 19 Novartis AG. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 20 F.Hoffman La Roche Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 21 Sanofi : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 23 Theravence Biopharma : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 24 Vertex Pharmaceuticals Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 25 Others : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)

Frequently Asked Question

What is the size of Respiratory Tract Infection Treatment Market?

The market for Respiratory Tract Infection Treatment Market is expected to reach USD$ 59,957.3 Mn in 2025

What is the Respiratory Tract Infection Treatment Market CAGR?

The Respiratory Tract Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 6.2 %.

What is the Forecast period considered for Respiratory Tract Infection Treatment Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Respiratory Tract Infection Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Abbott Laboratories, Abbvie Inc., AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –